Search
Abametapir
go.drugbank.com/drugs/DB11932ApprovedAbametapir is a novel pediculicidal metalloproteinase inhibitor used to treat infestations of head lice. … [A216183] Topical pediculicides generally lack adequate ovicidal activity,[A216183] including standard-of-care treatments such as [permethrin], and many require a second administration 7-10 days following
Delafloxacin
go.drugbank.com/drugs/DB11943ApprovedInvestigationalDelafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections,
Lemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigationalbeginning of a new wave of treatment options for patients suffering from insomnia. … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Duvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalcan produce a broad adaptative and innate immune cell inhibitory activity. … All the work around duvelisib showed that this agent is a potent inhibitor of both forms.[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585]
Entrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.[A183929]
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexAvatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[A33095] Thrombocytopenia is a common complication in patients suffering from chronic liver disease, occurring as a result of liver disease or a consequence of interferon-based antiviral therapy. … [L2927] _Doptelet_ (Avatrombopag) is the first orally administered treatment option for patients with chronic liver disease, allowing a large population of patients to avoid a platelet transfusion before
Fostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalRecently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK
Alpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalIt works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival … Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexTecovirimat
go.drugbank.com/drugs/DB12020ApprovedInvestigationalHowever, there have been longstanding concerns that smallpox may be used as a bioweapon.[A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. … The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980.
Letermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigational[L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.